INFLAMMATION DRIVES DECLINE IN NAD+
NAD+ decline and chronic inflammation have long been separately associated with aging and age-related disease. Recent research has shown that the twophenomena are linked, and that chronic inflammation is actually a driver of NAD+ decline.

NAD+ decline and degradation

Scientists have known for some time that NAD+ levels decrease with age, but it hasnot been clear whether this is because not enough NAD+ is being manufactured, or because the NAD+ itself is somehow degrading.

Recent findingsfrom one of our key research partners, the Buck Institute forResearch on Aging, show that the cause is both.

How doesinflammation cause NAD+ decline?

Senescent cells,which stop dividing in response to DNA damage (a hallmark of aging),release inflammatory proteins. As senescent cells build up in tissuesover the course of a lifetime, they trigger chronic inflammation.
This inflammation results in the expression of a protein called CD38 (cyclic ADP ribose hydrolase), which in turn degrades NAD+.

NAD+ degradation like this can lead to lowered cellular energy production, weakened cellular metabolism and less active sirtuins, which have widespread anti-aging properties.

New opportunities for NAD+ boosting

Currently, the most common way to replenish the body’s NAD+ is by supplementing with intermediates like NMN, which helps to support cell survival and regulate inflammation.

With research showing that blocking CD38 activity in older animals restores NAD+ levels in specific tissues, there is now an opportunity to create therapeutic interventions that prevent degradation of NAD+ caused by inflammation.

Combining both approaches to healthy NAD+ levels – boosting and preventing its degradation – will enable us to attack on two fronts in the fight against aging and age-related disease.

INFLAMMATION DRIVES DECLINE IN NAD+
NAD+ decline and chronic inflammation have long been separately associated with aging and age-related disease. Recent research has shown that the twophenomena are linked, and that chronic inflammation is actually a driver of NAD+ decline.

NAD+ decline and degradation

Scientists have known for some time that NAD+ levels decrease with age, but it hasnot been clear whether this is because not enough NAD+ is being manufactured, or because the NAD+ itself is somehow degrading.

Recent findingsfrom one of our key research partners, the Buck Institute forResearch on Aging, show that the cause is both.

How doesinflammation cause NAD+ decline?

Senescent cells,which stop dividing in response to DNA damage (a hallmark of aging),release inflammatory proteins. As senescent cells build up in tissuesover the course of a lifetime, they trigger chronic inflammation.
This inflammation results in the expression of a protein called CD38 (cyclic ADP ribose hydrolase), which in turn degrades NAD+.

NAD+ degradation like this can lead to lowered cellular energy production, weakened cellular metabolism and less active sirtuins, which have widespread anti-aging properties.

New opportunities for NAD+ boosting

Currently, the most common way to replenish the body’s NAD+ is by supplementing with intermediates like NMN, which helps to support cell survival and regulate inflammation.

With research showing that blocking CD38 activity in older animals restores NAD+ levels in specific tissues, there is now an opportunity to create therapeutic interventions that prevent degradation of NAD+ caused by inflammation.

Combining both approaches to healthy NAD+ levels – boosting and preventing its degradation – will enable us to attack on two fronts in the fight against aging and age-related disease.